ArticleNature communications2026
G-quadruplex homeostasis is a determinant of PARP inhibitor toxicity in BRCA2-deficient cells.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Inhibition of PARPs is a key strategy to treat tumours with defects in homologous recombination (HR), including those with mutations in the tumour suppressor gene BRCA2. PARP inhibitors generate replication stress, creating a dependence on HR to repair the resulting DNA damage. However, the DNA lesions generated upon PARP inhibition that impede replication fork progression and trigger a requirement for BRCA2 in cell survival are poorly defined. Here, we demonstrate that elevated levels of G-quadruplex (G4) DNA structures is a determinant of genome instability and PARP inhibitor toxicity, while suppressing these structures results in PARP inhibitor resistance. The HUWE1-associated stress response protein HAPSTR1 and BRCA2 function in parallel pathways to PARP1/PARP2 to suppress G4 levels during S-phase. Mechanistically, PARP1/PARP2 disruption in HAPSTR1 or BRCA2-deficient cells leads to G4-replication conflicts, ssDNA gaps, replication-associated DNA damage and genome instability. HAPSTR1 turnover is regulated through HUWE1-dependent proteasome degradation. As such, HUWE1 disruption results in elevated HAPSTR1 and suppression of elevated G4 levels in BRCA2-deficient cells, resulting in PARP inhibitor resistance. Together, these data identify G4 structures as a determinant of PARP inhibitor toxicity, while the HAPSTR1/HUWE1 axis is essential to suppress these structures and confer PARP inhibitor resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.